The Biggest Discussions in Retina from the 2022 ASRS Annual Meeting

July 20, 2022
Connor Iapoce

Connor Iapoce is an associate editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at ciapoce@mjhlifesciences.com.

This episode of DocTalk features 5 expert retina specialists discussing the top line data from the conference.

This past week, the American Society of Retina Specialists (ASRS) held its 40th Annual Meeting in New York City to discuss landmark data and the newest advancements in retina care.

The HCPLive team was on-site at the Javits Center in Manhattan conducting interviews with expert retina specialists on topics including drugs for neovascular age-related macular degeneration (nAMD) and geographic atrophy as well as landmark trials including the phase 3 TENAYA and LUCERNE trials.

On this episode of DocTalk, we share the biggest highlights and the biggest news from our conversations at the meeting with 5 expert clinicians. 

- Veeral Sheth, MD, Unviersity Retina discussed the Archway trial of the port delivery system (PDS) with ranibizumab and fluctuations in central subfield thickness (CST) over 96 weeks.

- Rishi Singh, MD, Cleveland Clinic Florida discussed the promising durability and safety of EYP-1901 with Vorolanib for the maintenance of nAMD.

- David Lally, MD, New England Retina Associates highlighted the post-hoc analysis of the GATHER1 clinical trial on avancicaptad pegol and how the agent led to a reduction in GA lesion gorwth across all distances from the foveal center point compared to sham.

- Aleksandra Rachitskaya, MD, Cleveland Clinic Cole Eye Institute, discussed the post-hoc analysis of the Phase 3 Archway trial and vision outcomes with the prescence of retinal fluid.

- Arshad Khanani, MD, Sierra Eye Associates presented two-year data from the Phase 3 TENAYA and LUCERNE sutides on the efficacy, durability, and safety of faricimab for nAMD treatment.

We hope you enjoy the episode. Check out our full coverage of the 2022 ASRS Annual Meeting here.


x